Direkt zum Inhalt

Seifert, Roland ; Schächtele, C.

Studies with protein kinase C inhibitors presently available cannot elucidate the role of protein kinase C in the activation of NADPH oxidase

Seifert, Roland und Schächtele, C. (1988) Studies with protein kinase C inhibitors presently available cannot elucidate the role of protein kinase C in the activation of NADPH oxidase. Biochemical and biophysical research communications 152 (2), S. 585-592.

Veröffentlichungsdatum dieses Volltextes: 26 Jan 2012 08:33
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.23268


Zusammenfassung

The effects of various protein kinase C (PKC) inhibitors on NADPH oxidase (NO) activation by the phorbol ester PMA and by the chemotactic peptide FMLP were studied. H-7 reduced the effects of both stimuli in human neutrophils (HN) and HL-60 cells by 13-63%. Polymyxin B did not inhibit NO activation by PMA and FMLP in HN and reduced the effects of both stimuli in HL-60 cells by 27-55%. Retinal and ...

The effects of various protein kinase C (PKC) inhibitors on NADPH oxidase (NO) activation by the phorbol ester PMA and by the chemotactic peptide FMLP were studied. H-7 reduced the effects of both stimuli in human neutrophils (HN) and HL-60 cells by 13-63%. Polymyxin B did not inhibit NO activation by PMA and FMLP in HN and reduced the effects of both stimuli in HL-60 cells by 27-55%. Retinal and retinoic acid enhanced the effects of PMA and FMLP in HL-60 cells and of FMLP in HN up to 4.5-fold. In contrast, retinoic acid inhibited the effect of PMA in HN. In the presence of cytochalasin B, retinal inhibited the effect of FMLP in HN, whereas retinoic acid inhibited NO activation by FMLP in both cell types. The dual PKC/calmodulin inhibitors trifluoperazine and W-7 abolished NO activation by PMA and FMLP in HN and HL-60 cells. Thus, the effects of PKC inhibitors on NO activation exhibit (1) cell type specificity, (2) stimulus dependency and (3) no correlation with in vitro inhibition of PKC. Our results suggest that studies with PKC inhibitors presently available cannot clarify the role of PKC in NO activation.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftBiochemical and biophysical research communications
Verlag:Elsevier
Band:152
Nummer des Zeitschriftenheftes oder des Kapitels:2
Seitenbereich:S. 585-592
Datum1988
InstitutionenChemie und Pharmazie > Institut für Pharmazie > Lehrstuhl Pharmakologie und Toxikologie (Prof. Schlossmann, ehemals Prof. Seifert)
Identifikationsnummer
WertTyp
2835037PubMed-ID
Klassifikation
NotationArt
1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineMESH
Cytochalasin B/pharmacologyMESH
Enzyme Activation/drug effectsMESH
FemaleMESH
HumansMESH
Isoquinolines/pharmacologyMESH
MaleMESH
N-Formylmethionine Leucyl-Phenylalanine/pharmacologyMESH
NADH, NADPH Oxidoreductases/metabolismMESH
Neutrophils/enzymologyMESH
Piperazines/pharmacologyMESH
Protein Kinase C/physiologyMESH
Superoxides/metabolismMESH
Tetradecanoylphorbol Acetate/pharmacologyMESH
Tumor Cells, CulturedMESH
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
600 Technik, Medizin, angewandte Wissenschaften > 615 Pharmazie
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenUnbekannt / Keine Angabe
URN der UB Regensburgurn:nbn:de:bvb:355-epub-232686
Dokumenten-ID23268

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben